Introduction
On June 11, 2009 , the World Health Organization (WHO) announced a pandemic influenza caused by pandemic (H1N1) 2009 virus. Since then, numerous reports describing the clinical course of the disease in a range of patient groups have been published, but there are important discrepancies regarding the possible threats connected with pandemic influenza. Certainly, the number of deaths caused by pandemic (H1N1) 2009 virus is considerably lower than the number predicted by WHO. Nevertheless, authors of numerous studies agree that the course of the disease in patients subject to immune suppressive treatment may be severe, and often even life-threatening. Up to the present, only a few studies describing the course of the disease in children undergoing treatment for cancer have been published [1, 2] .
The aim of the current work was to analyze the clinical course of pandemic (H1N1) 2009 influenza in children with neoplastic diseases or severe aplastic anemia. The effects of the antiviral treatment were also evaluated. The authors' own experience regarding the usefulness of diagnostic tests in clinical practice was presented, and an attempt to identify risk factors predictive for the severity of the clinical course of the disease was undertaken.
Material and method
On November 25, 2009, the first case of pandemic (H1N1) influenza in the Department of Pediatrics, Hematology, Oncology and Endocrinology at Medical University of Gdansk (Poland) was diagnosed in a 4-year-old boy who had just finished a course of chemotherapy for pre-B-cell non-Hodgkin's lymphoma, and consequently severe myelosuppression developed for a period of 10 days prior to the diagnosis of pandemic (H1N1) 2009 influenza. The patient was manifesting signs of respiratory tract infection for 3 days while visiting his parents, when sudden rapid deterioration of his general condition occurred. A reverse transcription polymerase chain reaction (RT-PCR) test performed at that time confirmed pandemic (H1N1) 2009 influenza infection. He had the first diagnosed case of pandemic (H1N1) 2009 influenza in the pediatric hematology/oncology ward in Gdansk. Our study started at the same time. The inclusion criterion was hospitalization in our department at the time of the first influenza diagnosis; 37 children treated for onco-hematological disorders were enrolled in the study: 11 children with acute lymphoblastic leukemia (ALL), 7 patients with acute myeloblastic leukemia (AML), 4 children with non-Hodgkin lymphoma (NHL) and 1 with Hodgkin lymphoma (HL), 2 patients with severe aplastic anemia (SAA) and 12 children with solid tumors (3 with rhabdomyosarcoma, 2 with Ewing sarcoma, 2 with Wilms tumor, 2 with medulloblastoma, 1 with schwannoma malignum, 1 with testis tumor and 1 with neuroblastoma). The group was comprised of 23 boys (62%) and 14 girls (38%; ratio 1.64:1). The age of the patients ranged from 6.5 months to 17.5 years (mean 9.3 years, median 9.1 years, SD 5.75). The spread of the virus was limited to the 37 children who were in the department at the time of the pandemia (Figure 1 ). Pandemic (H1N1) 2009 influenza infection was diagnosed in each patient on the basis of a positive RT-PCR test that was performed in all 37 patients. The patients were subject to two diagnostic tests: the screening one-step immunochromatographic influenza A/B test (GECKO Pharma Vertribe GmbH) [3] and an RT-PCR test using the RealTime Ready Influenza A/H1N1 Detection Set together with RealTime Ready RNA Virus Master Kit for LightCycler 2.0 (Roche). Additionally, 17 patients were also subjected to the screening nasal-swab test. A negative result of the screening test was always verified by a molecular test. Sensitivity and specificity of the screening test was hence evaluated along with its negative and positive predictive value.
The analysis comprised the assessment of the number of episodes of pandemic (H1N1) 2009 influenza in all 37 patients and evaluation of clinical signs and symptoms of the infection. Patients diagnosed with pandemic (H1N1) 2009 influenza were subject to isolation. Sixteen of them were transferred to the isolation unit; 2 patients in severe general condition were transferred to the intensive care unit; and 2 children who presented with no clinical signs of the disease received antiviral treatment at home. Children in whom the molecular test ruled out pandemic (H1N1) 2009 influenza remained hospitalized in the hematology/oncology ward. Family visits were banned for a short interval. Educational meetings aimed at raising the awareness of virus prophylaxis were organized for clinical staff, parents and patients. All student and resident rotations were discontinued. After introduction of the isolation procedure, no more new cases of pandemic (H1N1) 2009 influenza in the hematology/oncology ward were diagnosed.
Patients with pandemic (H1N1) 2009 influenza were subdivided into two groups with respect to the severity of clinical symptoms. Group I comprised patients with no or only minor clinical signs of the infection who did not need oxygen supplementation. Patients in group II required respiratory support (respiratory therapy or supplemental oxygen therapy). Also, the putative effect of the primary clinical diagnosis (hematological disorders: ALL, AML, NHL, SAA vs. solid tumors) on the severity of the clinical course of pandemic (H1N1) 2009 influenza was evaluated. Furthermore, the relation between the presence of lymphocytopenia and its duration prior to infection and until eventual contraction of the pandemic (H1N1) 2009 virus, as well as the severity of the clinical course of the disease, was analyzed. Blood counts were performed every day during the study. Lymphocytopenia was defined as absolute lymphocyte count under 1000 cells per 1 µl. Analysis of the eventual therapeutic effect of oseltamivir and evaluation of treatment-related side effects were also performed. The dose of oseltamivir was adjusted for the weight and age of the patients in accordance with the recommendations of the pharmaceutical company.
The clinical findings were monitored by daily physical examinations. For data collection, a standardized study protocol was used.
All research was approved by the Independent Bioethics Committee for Scientific Research at the Medical University of Gdansk.
Statistical methods
All the data on patients' characteristics and obtained results were encoded and transferred to computer databases. The data that had no normal probability distribution were analyzed with use of non-parametric tests (Mann-Whitney U test 
Results
On the basis of the results of molecular RT-PCR testing, pandemic (H1N1) 2009 influenza infection was diagnosed in 20 of 37 children (54%). Type A influenza screening nasal-swab testing was performed in 17 patients; for 13 of them a negative result was obtained. After verification of the screening result by a molecular RT-PCR test, in 7 of 13 cases the results turned out to be false-negative. The sensitivity and specificity of the screening nasal-swab test was determined (36.4% and 100%, respectively). The calculated positive predictive value was 100%, whereas the negative predictive value was 46.2%. The time period between the first and the last confirmed pandemic (H1N1) 2009 influenza infection in the hematology/oncology unit was 7 days (Figure 1 ).
Among clinical signs in patients diagnosed with pandemic (H1N1) 2009 influenza, the most commonly reported were cough (14 patients) and fever exceeding 38.5°C (13 patients). The other symptoms reported by the patients included dyspnea, myalgia, arthralgia, diarrhea and nausea/vomiting (Table 1) .
Three patients had signs of inflammation on chest radiographs, described further as "ground-glass"-like shadowing. Three of the patients presented with no clinical signs of the disease. Fifteen patients were assigned to group I (without need for oxygen supplementation therapy), including 12 patients with a mild clinical course of the disease and 3 asymptomatic patients. Five patients were assigned to group II (requiring oxygen supplementation or mechanical ventilation). One patient was subject to respiratory therapy (the chest CT revealed massive inflammatory lesions; Figure 2) , whereas the remaining 4 cases received supplemental oxygen therapy.
In all the patients diagnosed with pandemic (H1N1) 2009 influenza, as well as in all children who had contact with affected patients, oral oseltamivir therapy was started. Therapy lasted 5 to 14 days: the children in contact with the virus received therapy for 5 consecutive days, the patients diagnosed with influenza infection received 10 days of therapy, and 1 patient received the drug for 14 consecutive days. Side effects of the therapy in the form of nausea/vomiting were reported in 3 out of 37 patients; however, 2 of them also had concomitant rotavirus infection. Liver function did not worsen in any of the patients receiving oseltamivir. In the total group of 37 patients, no deaths related to pandemic (H1N1) 2009 influenza were reported up to the submission of our present report (observation period 16 months). The effect of the primary clinical diagnosis on the clinical course of influenza and its duration was also analyzed. All patients who required oxygen supplementation therapy had a hematological disorder: NHL, AML and SSA (2, 2 and 1 case, respectively). None of the patients undergoing therapy for a solid tumor required oxygen supplementation in the course of pandemic (H1N1) 2009 influenza. However, in children affected with pandemic (H1N1) 2009 influenza, no statistically significant difference was observed between the type of primary clinical diagnosis and necessity of respiratory support (p=0.266).
No relation between the presence of lymphocytopenia in patients when pandemic (H1N1) 2009 influenza occurred and the eventual contraction of the virus was observed (p=0.63). No effect of the duration of lymphocytopenia in patients prior to the appearance of pandemic (H1N1) 2009 influenza and the eventual contraction of the virus was observed (the mean duration of lymphocytopenia in non-infected patients vs. 
Discussion
There are opposing opinions regarding the threats related to infection with pandemic (H1N1) 2009 influenza virus. According to data presented by WHO at the conclusion of the pandemic influenza, which was announced on June 11, 2009, 18,500 people died, instead of the predicted 7,000,000. The data published every year with respect to seasonal flu show a significantly higher death rate (ca. 500,000 persons/ year). In view of these statistics, some experts claim that the risks related to pandemic (H1N1) 2009 influenza were misleadingly overestimated [4] . It appears, however, that in a group of patients undergoing immune suppressive treatment the disease can have a severe clinical course and even cause death. Furthermore, during the pandemic, there was no vaccination available against the new virus that was comprehensively investigated and indisputably safe. Therefore, some of the European Union (EU) countries, Poland included, did not decide to introduce it in clinical practice. It is generally acknowledged that children undergoing immune suppressive treatment usually are not capable of producing satisfactory levels of immunoglobulins after vaccination, which has already been proven in studies of the response of immunoincompetent children to vaccination against seasonal flu. [5] Since vaccinations have inferior efficacy in this particular group of patients, special emphasis should be given to annual vaccinations against influenza among medical personnel and patients' guardians who have contact with immunoincompetent children. These recommendations should be met not only with respect to seasonal flu and pandemic (H1N1) 2009 influenza, but with respect to all new emerging types of the virus [5] .
Because of the dangers related to influenza infection in the group of children undergoing immune suppressive treatment, particular attention should be given to procedures aimed at limiting the spread of the virus in the population [6, 7] . In our study, setting up a special isolation unit for children diagnosed with pandemic (H1N1) 2009 influenza, early introduction of chemoprophylaxis in all children who possibly had contact with the virus, and intensification of sanitary control resulted in the fact that the interval between the first and the last confirmed diagnosis of the disease in the patients was merely 7 days.
Most authors report that the clinical course of the new influenza is moderate [2, 8] . In our study a mild or asymptomatic course of pandemic (H1N1) 2009 influenza was observed in three-quarters of the patients. Furthermore, clinical signs typical for a flu-like infection (fever, cough, vomiting, myalgia and arthralgia) all resolved, leaving no permanent aftereffects. It has been suggested that in patients with immune deficiencies the clinical course of pandemic (H1N1) 2009 influenza can be severe and often life-threatening [6, [9] [10] [11] . In our group of children respiratory support was required in a quarter of cases. In our opinion, identification of patients at highest risk for a severe clinical course of influenza may have tremendous importance, especially in the context of future inevitable pandemics. It is generally acknowledged that influenza virus is particularly capable of modifying its antigens; therefore, it can be expected that efficacy of vaccination during one season will be doubtful in the next season. An attempt to determine simple, inexpensive and readily available risk factors predictive for the severity of the clinical course of influenza has been undertaken. The first of the parameters is the primary clinical diagnosis. It has been observed that all children undergoing treatment for solid tumors had an indolent course of pandemic (H1N1) 2009 influenza. Conversely, a severe course of the disease was observed exclusively in patients with hematological disorders. Nevertheless, no statistically significant difference in the severity of the disease was observed with respect to the primary clinical diagnosis, which may, however, be related to the small number of children in the study. It has been observed that the presence of lymphocytopenia and its duration, in particular, have an effect on the eventual contraction of the pandemic (H1N1) 2009 virus and also on the severity of the clinical course of influenza infection. In the available literature lymphocytopenia has already been reported as an independent risk factor predictive for a severe clinical course of pandemic (H1N1) 2009 influenza not only in the subgroup of immunoincompetent patients [12] [13] [14] . Therefore particular attention should be paid to children in whom lymphocytopenia develops in the course of the primary disease or during its treatment. The decision regarding performing diagnostic tests and starting antiviral prophylaxis should be taken immediately. The clinical course of pandemic (H1N1) 2009 influenza in the first of our patients diagnosed with pandemic (H1N1) 2009 influenza may serve as supporting evidence for this thesis. It appears that the start of the antiviral therapy in this patient took place belatedly, not until the third day after clinical signs of infection. It was, however, the first case of pandemic (H1N1) 2009 influenza diagnosed in our hematology/oncology center. At that moment, the awareness of health hazards related to influenza pandemics was inadequate.
In a few reports authors have suggested that in immune competent patients antiviral treatment should not be started after 48 hours from the disease onset [15] . However, in patients with immune deficiencies viral replication may be prolonged, and hence starting antiviral therapy even 48 hours after the first symptoms may still be beneficial [13] , as observed in our case of the 4-year-old boy. The rest of our patients had antiviral therapy started within first 48 hours.
Proper pandemic (H1N1) 2009 influenza diagnostics is another important issue. In the analyzed group of patients, all cases of pandemic (H1N1) 2009 influenza were diagnosed based on the results of RT-PCR testing performed on the nasopharyngeal swabs as recommended in the literature [1, 6, 8, 16] . The fact that 17 out of 37 patients also had a screening test allowed evaluation of its application for pandemic influenza diagnostics. It has been shown that the low sensitivity and low negative prognostic value of the fast screening test (36% and 46.2% respectively) limit its clinical application. It is of particular importance in the group of immunoincompetent children, since any delay in the diagnosis of pandemic (H1N1) 2009 influenza and, thus, postponement of antiviral therapy may result in an unfavorable final outcome of the disease. [6, 17] The clinical manifestations of pandemic (H1N1) 2009 influenza in immunoincompetent children are analogous to the symptoms observed in general population. A severe clinical course of the disease was observed among patients with hematological disorders, especially those presenting with preceding lymphocytopenia. It appears that rapid diagnosis and early introduction of antiviral therapy have a decisive effect on the final outcome of the disease. We believe that rapid screening tests for influenza A infection should not be used in a clinical setting because of their low sensitivity and low negative predictive value. RT-PCR remains the best option in pandemic (H1N1) 2009 influenza testing.
